Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab

In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during dur...

Full description

Bibliographic Details
Main Authors: Erwin H.J. Tonk, Anne S.R. van Lindert, Joost J.C. Verhoeff, Karijn P.M. Suijkerbuijk
Format: Article
Language:English
Published: Karger Publishers 2019-08-01
Series:Case Reports in Oncology
Subjects:
Immune checkpoint inhibitor
Anti-PD-L1
NSCLC
Adjuvant
Pneumonitis
Online Access:https://www.karger.com/Article/FullText/502202

Internet

https://www.karger.com/Article/FullText/502202

Similar Items